Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11930
Title: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Austin Authors: Andrews, Miles C;Behren, Andreas;Chionh, Fiona;Mariadason, John M ;Vella, Laura J;Do, Hongdo;Dobrovic, Alexander ;Tebbutt, Niall C ;Cebon, Jonathan S 
Affiliation: Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia
Issue Date: 4-Nov-2013
Publication information: Journal of Clinical Oncology 2013; 31(35): e448-51
URI: http://ahro.austin.org.au/austinjspui/handle/1/11930
DOI: 10.1200/JCO.2013.50.4118
URL: https://pubmed.ncbi.nlm.nih.gov/24190114
Type: Journal Article
Subjects: Cell Proliferation.drug effects
Colonic Neoplasms.drug therapy.genetics.pathology
Humans
Imidazoles.therapeutic use
MAP Kinase Kinase 1.antagonists & inhibitors.metabolism
MAP Kinase Kinase 2.antagonists & inhibitors.metabolism
Male
Middle Aged
Mutation
Oximes.therapeutic use
Protein Kinase Inhibitors.therapeutic use
Proto-Oncogene Proteins.genetics
Proto-Oncogene Proteins B-raf.antagonists & inhibitors.metabolism
Pyridones.therapeutic use
Pyrimidinones.therapeutic use
Treatment Outcome
ras Proteins.genetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Nov 29, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.